Public Health and Nephrology: Contributions of Epidemiology to the Study, Understanding, Prevention and Treatment of Kidney Disease.

Contrib Nephrol

School of Primary Care, Population Science and Medical Education, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom.

Published: April 2022

Kidney disease is frequently described as a public health problem. This chapter will unpack what we mean by "public health" and by "taking a public health approach." We will consider the global burden of kidney diseases and their determinants, with a focus on chronic kidney disease. We will explore the aetiology of chronic kidney disease across the life course and the way in which kidney health frequently reflects inequities in societal health, therefore requiring a public health response. We will describe some of the public health endeavours that help address these problems and then introduce epidemiology as the core science of public health. We will describe the common epidemiological study designs with a focus on observational studies and explore the role of the various study designs in addressing different types of research question, and thereby contributing to distinct aspects of disease understanding. We will introduce concepts of primary and secondary prevention and explore the ways in which the application of different epidemiological study designs has contributed to the knowledge and understanding of kidney diseases. We will discuss the strengths and weaknesses of different study designs and explain how epidemiological methods allow for the quantification of public health problems.

Download full-text PDF

Source
http://dx.doi.org/10.1159/000517671DOI Listing

Publication Analysis

Top Keywords

public health
28
kidney disease
16
study designs
16
health
8
kidney diseases
8
chronic kidney
8
will describe
8
epidemiological study
8
public
7
kidney
7

Similar Publications

Background: Pharmacoepidemiologic studies assessing drug effectiveness for Alzheimer's disease and related dementias (ADRD) are increasingly popular given the critical need for effective therapies for ADRD. To meet the urgent need for robust dementia ascertainment from real-world data, we aimed to develop a novel algorithm for identifying incident and prevalent dementia in claims.

Method: We developed algorithm candidates by different timing/frequency of dementia diagnosis/treatment to identify dementia from inpatient/outpatient/prescription claims for 6,515 and 3,997 participants from Visits 5 (2011-2013; mean age 75.

View Article and Find Full Text PDF

Background: Availability of amyloid modifying therapies will dramatically increase the need for disclosure of Alzheimer's disease (AD) related genetic and/or biomarker test results. The 21st Century Cares Act requires the immediate return of most medical test results, including AD biomarkers. A shortage of genetic counselors and dementia specialists already exists, thus driving the need for scalable methods to responsibly communicate test results.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA.

Background: Some types of cancer have been associated with reduced risk of clinical dementia diagnosis. Whether cancer history may be associated with neuropathological features of neurodegeneration or cerebrovascular disease is not well understood. We investigated the relation between cancer diagnosis and brain pathology in a sample of community-based research volunteers enrolled in an Alzheimer's Disease Research Center (ADRC) cohort.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, Netherlands.

Background: The first disease-modifying treatments (DMTs) for Alzheimer's disease (AD) have been approved in the USA, marking profound changes in AD-diagnosis and treatment. This will bring new challenges in terms of clinician-patient communication. We aimed to collect the perspectives of memory clinic professionals regarding the most important topics to address and what (tools) would support professionals and their patients and care partners to engage in a meaningful conversation on whether (or not) to initiate treatment.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

The George Institute for Global Health, University of New South Wales, Imperial College London, Sydney, NSW, Australia.

Background: Recent growth in the functionality and use of technology has prompted an increased interest in the potential for remote or decentralised clinical trials in dementia. There are many potential benefits associated with decentralised medication trials, but the field is currently lacking specific recommendations for their delivery in the dementia field.

Method: A modified Delphi method engaged a panel with substantial expertise in dementia trial design and delivery and backgrounds that included neurology, psychiatry, pharmacology and psychology, to develop recommendations for the conduct of decentralised medication trials in dementia prevention.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!